Umut Özbek
Eli Lilly (United States)(US)Eli Lilly (Singapore)(SG)
Publications by Year
Research Areas
Hematopoietic Stem Cell Transplantation, Breast Cancer Treatment Studies, Hepatocellular Carcinoma Treatment and Prognosis, Acute Lymphoblastic Leukemia research, Head and Neck Cancer Studies
Most-Cited Works
- → Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma(2019)754 cited
- → An early-biomarker algorithm predicts lethal graft-versus-host disease and survival(2017)219 cited
- → MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD(2018)203 cited
- → Proteomics profiling of arginine methylation defines PRMT5 substrate specificity(2019)169 cited
- → Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy(2010)147 cited
- → Survival signal REG3α prevents crypt apoptosis to control acute gastrointestinal graft-versus-host disease(2018)134 cited
- → Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti–PD‐1 therapy(2020)129 cited
- → What hasGWASdone forHLAand disease associations?(2017)106 cited
- → The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease(2019)105 cited